MAK CAPITAL ONE LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001385702

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 17 positions · Total reported value $713.79M · Top-10 concentration 82.5% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 40.9% · 1 new · 3 cut · 5 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +22.9% · vs SPY +8.1% · Prev Value $583.32M — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, MAK CAPITAL ONE LLC disclosed 17 equity positions with a combined reported value of $713.79M. The filing implies a focused portfolio: its ten largest positions account for 82.5% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were AGYS ($124.64M), GGAL ($74.34M), ACHC ($71.85M). By sector, the heaviest allocations are Health Care 43.8%, Technology 17.5%. Versus the prior quarter, allocation shifted toward Health Care (+14.1pp) and away from Financials (-2.1pp), Technology (-2.7pp).

Versus the prior quarter, MAK CAPITAL ONE LLC opened 1 new positions, trimmed 3 and fully exited 5, a turnover rate of 40.9% of positions. The portfolio's overlap with the prior quarter was 73% of names.

The largest new positions opened in Q2 2026 were CAI ($34.52M).

Of the 5 positions fully exited versus the prior quarter, the largest were COUR ($32.70M), UDMY ($16.90M), PLX ($7.69M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • CAI CARIS LIFE SCIENCES INC · $34.52M

Fully Exited (vs previous quarter)

  • COUR COURSERA INC · prev qtr: $32.70M
  • UDMY UDEMY INC · prev qtr: $16.90M
  • PLX PROTALIX BIOTHERAPEUTICS INC · prev qtr: $7.69M
  • FVRR FIVERR INTL LTD F · prev qtr: $806.40K
  • SGMOQ SANGAMO THERAPEUTICS INC · prev qtr: $138.64K

Insider Transactions (Form 4)

Latest MAK CAPITAL ONE LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Mak Capital One is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 17 US equity positions with a combined value of $713.79M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-73772 (status: Approved), registered 2012-03-30
  • Regulatory AUM (Form ADV): $1.99B as of 2026-03-26
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 1 hedge funds
  • Website: makcapitalfund.com

Portfolio Structure

  • 17 positions · $713.79M reported value (Q2 2026)
  • Top 10 holdings = 82.5% of reported value
  • Largest position: AGYS (AGILYSYS INC) at 17.5%
  • Average position size: $41.99M

Sector Tilt

  • Health Care 43.8%
  • Information Technology 17.5%
  • Financials 16.2%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 1 new, 6 added, 3 reduced, 5 exited
  • 7 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund appears to maintain a cautious stance with a slight bias towards health care, indicating a preference for sectors that may offer stability or growth amid market uncertainty. The addition of new positions and the increase in certain holdings suggest a focus on potential growth opportunities. 2. Key Moves: - Added: QURE (Uniqure NV), a biotech company, and CAI (Caris Life Sciences Inc), a biotech company; increased holdings in ANNX (Annexon Inc) by 24.1%. - Reduced: SKY (Champion Homes Inc), a consumer discretionary company, by 36.8%. - Hold: AGYS (Agilysys Inc), GGAL (Grupo Financiero Galicia S.A), ACHC (Acadia Healthcare Company Inc), AUTL (Autolus Therapeutics Ltd), CLPT (Clearpoint Neuro Inc), SUPV (Grupo SuperVIELLE S.A), and CAI (Caris Life Sciences Inc). - New: CAI (Caris Life Sciences Inc). 3. Portfolio Structure: - Passive/Active: The fund appears to be more active, as indicated by the additions, reductions, and changes in shareholdings. - Sector Bias: The portfolio shows a significant bias towards the health care sector, with seven of the top holdings in this sector. - Risk Appetite: The risk appetite seems moderate, with a focus on growth sectors but also holding onto established companies with a "hold" strategy. 4. Per-Holding One-Liner: - AGYS (Agilysys Inc): A provider of cloud computing solutions for the hospitality industry. - GGAL (Grupo Financiero Galicia S.A): A financial services company operating in Mexico. - ACHC (Acadia Healthcare Company Inc): A provider of inpatient and outpatient behavioral health services. - QURE (Uniqure NV): A biotechnology company focusing on the development of therapies for rare genetic diseases. - SKY (Champion Homes Inc): A homebuilder and developer of residential properties. - AUTL (Autolus Therapeutics Ltd): A biopharmaceutical company developing novel cancer immunotherapies. - CLPT (Clearpoint Neuro Inc): A biotechnology company focused on developing treatments for neurological disorders. - SUPV (Grupo SuperVIELLE S.A): A food and beverage company in Argentina. - CAI (Caris Life Sciences Inc): A biotechnology company that provides precision medicine services. - ANNX (Annexon Inc): A biotechnology company developing therapies for rare genetic diseases. 5. One-Sentence Style Summary: The fund maintained a diversified portfolio with a focus on health care, adding to growth-oriented biotech companies while reducing exposure to consumer discretionary sectors.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 43.8%
Technology 17.5%
Financials 16.2%
Energy 2.3%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 1.19M $124.64M 17.46%
17.46%
Hold
2 1.49M $74.34M 10.41%
10.41%
Add
3 2.43M $71.85M 10.06%
10.06%
Hold
4 1.23M $56.75M 7.95%
7.95%
Add
5 632.37K $55.72M 7.81%
7.81%
Reduce
6 33.62M $53.79M 7.54%
7.54%
Hold
7 2.38M $42.39M 5.94%
5.94%
Add
8 4.25M $41.05M 5.75%
5.75%
Hold
9 1.94M $34.52M 4.84%
4.84%
New
10 5.86M $33.47M 4.69%
4.69%
Add
11 28.81M $23.71M 3.32%
3.32%
Add
12 5.19M $21.59M 3.02%
3.02%
Reduce
13 1.28M $20.05M 2.81%
2.81%
Reduce
14 4.78M $17.48M 2.45%
2.45%
Hold
15 536.83K $16.21M 2.27%
2.27%
Hold
16 1.03M $14.76M 2.07%
2.07%
Add
17 12.17M $11.47M 1.61%
1.61%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 70% R 70% F1 70% (modelled on 2026-Q1; 7/10 hit)

Low-confidence forecast This fund replaces about 26% of its Top-10 each quarter and backtests at F1 75% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (10 quarters)

Avg precision 77% · recall 74% · F1 75% · avg rank error 2.3 · Top-10 turnover 26%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 86% 60% 71% AGYS · SKY · YTRA · IE · HTOO · MTCH · HTOOW SKY · AGYS · HSII · YTRA · IE · SUPV · LOMA · HTOO · IRS · HTOOW
2024-Q2 90% 100% 95% SKY · AGYS · HSII · YTRA · IE · SUPV · LOMA · HTOO · IRS · HTOOW SKY · AGYS · HSII · IE · YTRA · SUPV · LOMA · HTOO · HTOOW
2024-Q3 100% 90% 95% SKY · AGYS · HSII · IE · SUPV · YTRA · LOMA · HTOO · HTOOW SKY · AGYS · HSII · LOMA · YTRA · SUPV · SBSW · IE · HTOO · HTOOW
2024-Q4 70% 88% 78% SKY · AGYS · HSII · LOMA · SUPV · YTRA · SBSW · IE · HTOO · HTOOW SKY · HSII · AGYS · SUPV · LOMA · YTRA · SBSW · LASR
2025-Q1 75% 75% 75% SKY · HSII · SUPV · AGYS · LOMA · YTRA · SBSW · LASR SKY · HSII · SUPV · CTRA · LOMA · AGYS · YTRA · LAB
2025-Q2 88% 70% 78% SKY · HSII · SUPV · CTRA · LOMA · AGYS · YTRA · LAB SKY · HSII · INTC · AUTL · AGYS · SUPV · ICLR · LOMA · CTRA · YTRA
2025-Q3 60% 60% 60% SKY · HSII · INTC · AUTL · AGYS · SUPV · ICLR · LOMA · CTRA · YTRA SKY · HSII · AUTL · AGYS · PRO · LAB · SUPV · YTRA · DAWN · PESI
2025-Q4 60% 60% 60% SKY · HSII · AUTL · PRO · AGYS · LAB · SUPV · YTRA · DAWN · PESI SKY · GGAL · QCOM · AUTL · SUPV · AGYS · COUR · LAB · UDMY · YTRA
2026-Q1 70% 70% 70% SKY · GGAL · QCOM · AUTL · SUPV · AGYS · LAB · COUR · UDMY · YTRA AGYS · SKY · GGAL · ACHC · AUTL · SUPV · COUR · ANNX · LAB · LODE
2026-Q2 ★ 70% 70% 70% AGYS · SKY · GGAL · ACHC · AUTL · SUPV · COUR · ANNX · LAB · LODE AGYS · GGAL · ACHC · QURE · SKY · AUTL · CLPT · SUPV · CAI · ANNX

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did MAK CAPITAL ONE LLC buy in 2026-Q2?

In its 2026-Q2 13F filing, MAK CAPITAL ONE LLC reported 17 equity positions worth $713.79M in aggregate; its largest disclosed positions were AGYS ($124.64M), GGAL ($74.34M), ACHC ($71.85M).

How large is MAK CAPITAL ONE LLC's portfolio?

MAK CAPITAL ONE LLC reported $713.79M of long equity holdings across 17 positions as of 2026-Q2. Top-10 holdings account for 82.5% of reported value.

What is MAK CAPITAL ONE LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/mak-capital-one/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →